Literature DB >> 4039649

Substitution and primary dependence studies in animals.

J H Woods, D E Gmerek.   

Abstract

The mixed agonist-antagonist analgesics buprenorphine, butorphanol, nalbuphine, pentazocine and picenadol were compared to the prototype mu and kappa agonists morphine and Mr 2033, respectively, in the following tests in rhesus monkeys: overt behavioral effects upon acute administration in drug-naive animals; discriminative stimulus properties in monkeys trained to respond to either etorphine or ethylketazocine; self-administration of the test agent relative to codeine; single dose suppression and precipitation in withdrawn and non-withdrawn morphine-dependent monkeys, respectively; and primary addiction studies in drug-naive animals. Whereas both buprenorphine and nalbuphine precipitate withdrawal in morphine-dependent monkeys, withdrawal following chronic administration of buprenorphine resulted in no observable signs of abstinence, while nalbuphine withdrawal was similar to that seen in morphine-dependent monkeys. Butorphanol, pentazocine and picenadol all produced mild dependence of the kappa-type; that is, natural withdrawal behavior similar to that seen following chronic Mr 2033 administration.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4039649     DOI: 10.1016/0376-8716(85)90059-6

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  11 in total

1.  Abuse-related effects of µ-opioid analgesics in an assay of intracranial self-stimulation in rats: modulation by chronic morphine exposure.

Authors:  Ahmad A Altarifi; Kenner C Rice; S Stevens Negus
Journal:  Behav Pharmacol       Date:  2013-09       Impact factor: 2.293

Review 2.  The Rise and Fall of Kappa-Opioid Receptors in Drug Abuse Research.

Authors:  Matthew L Banks
Journal:  Handb Exp Pharmacol       Date:  2020

3.  Buprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawal.

Authors:  Carol A Paronis; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2010-11-04       Impact factor: 4.030

4.  Effects of morphine, naloxone, buprenorphine, butorphanol, haloperidol and imipramine on morphine withdrawal signs in cynomolgus monkeys.

Authors:  H Fukase; K Fukuzaki; T Koja; R Nagata; S E Lukas
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

5.  Effects of the kappa opioid agonist U50,488 and the kappa opioid antagonist nor-binaltorphimine on choice between cocaine and food in rhesus monkeys.

Authors:  S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2004-04-27       Impact factor: 4.530

6.  Comparison of the opioid receptor antagonist properties of naltrexone and 6 beta-naltrexol in morphine-naïve and morphine-dependent mice.

Authors:  Mary F Divin; M C Holden Ko; John R Traynor
Journal:  Eur J Pharmacol       Date:  2008-01-24       Impact factor: 4.432

7.  Mechanisms of withdrawal-associated increases in heroin self-administration: pharmacologic modulation of heroin vs food choice in heroin-dependent rhesus monkeys.

Authors:  S Stevens Negus; Kenner C Rice
Journal:  Neuropsychopharmacology       Date:  2008-08-13       Impact factor: 7.853

Review 8.  Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.

Authors:  Mark K Greenwald; Sandra D Comer; David A Fiellin
Journal:  Drug Alcohol Depend       Date:  2014-08-19       Impact factor: 4.492

9.  Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers.

Authors:  Sandra D Comer; Maria A Sullivan; Robert A Whittington; Suzanne K Vosburg; William J Kowalczyk
Journal:  Neuropsychopharmacology       Date:  2007-06-20       Impact factor: 7.853

10.  The discriminative stimulus effects of mecamylamine in nicotine-treated and untreated rhesus monkeys.

Authors:  Colin S Cunningham; Megan J Moerke; Lance R McMahon
Journal:  Behav Pharmacol       Date:  2014-08       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.